Effect of Coenzyme Q10 in Contrast Induced Nephropathy

Investigating the Effect of Coenzyme Q10 in Preventing Contrast Induced Nephropathy in Patients with Renal Failure Undergoing Coronary Angiography

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250513065714N2

Enrollment

156

Registered

2025-07-09

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast Induced Nephropathy. Chronic kidney disease (CKD)

Interventions

Intervention 1: Intervention group: Patients in the Intervention group received Coenzyme Q10 capsules (30 mg) twice daily, administered from two days before until three days after contrast exposure. T

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Stage 3 and 4 Chronic Kidney Disease Patients candidate for coronary angiography Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Requires dialysis Received contrast agents within the past seven days Received N-acetylcysteine within the past 48 hours

Design outcomes

Primary

Measure	Time frame
Serum Creatinine Level. Timepoint: Before contrast administration and 72 hours after contrast administration. Method of measurement: Laboratory Kit.;Glomerular Filtration Rate (GFR). Timepoint: Before contrast administration and 72 hours after contrast administration. Method of measurement: Laboratory Kit and its Calculation formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNoushin Bateni

Esfahan University of Medical Sciences

Bateni_noushin@resident.mui.ac.ir+98 31 3792 3131

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026